Pharmaceutical Care for Asthma Control Improvement (PHARMACI)-Study

This study has been completed.
Sponsor:
Information provided by:
University Ghent
ClinicalTrials.gov Identifier:
NCT00263159
First received: December 6, 2005
Last updated: December 19, 2007
Last verified: December 2007

December 6, 2005
December 19, 2007
January 2006
Not Provided
The difference between study groups in the change of asthma control from baseline and follow-up visits [ Time Frame: after 1, 3 and 6 months ]
The difference between study groups in the change of asthma control from baseline and follow-up visits (after 1, 3 and 6 months)
Complete list of historical versions of study NCT00263159 on ClinicalTrials.gov Archive Site
  • Peak flow [ Time Frame: after 3 and 6 months ]
  • Knowledge of asthma and treatment [ Time Frame: after 6 months ]
  • Asthma quality of life questionnaire (AQLQ) [ Time Frame: after 6 months ]
  • Therapy adherence
  • Inhalation techniques [ Time Frame: after 6 months ]
  • Smoking [ Time Frame: after 6 months ]
  • Asthma exacerbations [ Time Frame: after 6 months ]
  • General Practitioner (GP) visits, emergency room visits and hospitalisations
  • Working days lost and school days lost
  • Peak flow (after 3 and 6 months)
  • Knowledge of asthma and treatment (after 6 months)
  • Asthma quality of lifte AQLQ (after 6 months)
  • Therapy adherence (after 6 months)
  • Inhalation techniques (after 6 months)
  • Smoking (after 6 months)
  • Asthma exacerbations (after 6 months)
  • GP visits, emergency room visits and hospitalisations
  • Working days lost and school days lost
Not Provided
Not Provided
 
Pharmaceutical Care for Asthma Control Improvement (PHARMACI)-Study
Pharmaceutical Care for Asthma Control Improvement

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients.

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients. Patients will be randomly allocated to the control group (= no input from pharmacist) or intervention group (= with pharmaceutical care at baseline and follow-up visits over 6 months).

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Asthma
Procedure: Pharmaceutical care for asthma patients
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
221
October 2006
Not Provided

Inclusion Criteria:

  • Patients with persistent asthma
  • Asthma treatment for at least 12 months
  • Regular visitors of the participating community pharmacy

Exclusion Criteria:

  • Severe co-morbidity
  • > 10 pack-years smoking history
  • Asthma Control Test score < 15 or =25
Both
18 Years to 50 Years
No
Contact information is only displayed when the study is recruiting subjects
Belgium
 
NCT00263159
2005/320
No
Not Provided
University Ghent
Not Provided
Principal Investigator: Guy Brusselle, MD, PhD University Hospital, Ghent
University Ghent
December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP